Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Biosimilar (CinnaGen) vs Eylea in nAMD
NCT05587062Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Oct 2019
- Primary completion
- Jul 2022
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by CinnaGen. Primary endpoint: Proportion of patients achieving maintaining vision (losing <15 letter on ETDRS chart) at 52 weeks. Started Oct 2019; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05587062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05587062.